Compounds > nutlin 2
Page last updated: 2024-11-10

nutlin 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5288631
CHEMBL ID407632
SCHEMBL ID4323456
MeSH IDM0461686

Synonyms (9)

Synonym
cis-[4,5-bis-(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-[4-(2-hydroxyethyl)piperazin-1-yl]methanone
nutlin-2
DB02872
1RV1
CHEMBL407632 ,
SCHEMBL4323456
[(4s,5r)-4,5-bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-[4-(2-hydroxyethyl)piperazin-1-yl]methanone
bdbm50392531
2-(4-{[(4s,5r)-4,5-bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydro-1h-imidazol-1-yl]carbonyl}piperazin-1-yl)ethanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cellular tumor antigen p53Homo sapiens (human)Potency0.30000.002319.595674.0614AID243263
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)Potency0.30000.30000.30000.3000AID243263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cellular tumor antigen p53Homo sapiens (human)IC50 (µMol)0.14000.00060.88508.2000AID1118050
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)IC50 (µMol)0.14000.00060.358210.0000AID1118050; AID1195730; AID691697; AID754224
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (175)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein polyubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
blood vessel developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
blood vessel remodelingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of heart rateE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
atrioventricular valve morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
endocardial cushion morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ventricular septum developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
atrial septum developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
apoptotic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
traversing start control point of mitotic cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of cell population proliferationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to xenobiotic stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to toxic substanceE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to iron ionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of gene expressionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of protein processingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of neuron projection developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein ubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein sumoylationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein destabilizationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to magnesium ionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein localization to nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to cocaineE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
establishment of protein localizationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to etherE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of DNA-templated transcriptionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of mitotic cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to antibioticE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of protein export from nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to steroid hormoneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of muscle cell differentiationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
proteolysis involved in protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein autoubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cardiac septum morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein-containing complex assemblyE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to hydrogen peroxideE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to vitamin B1E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to alkaloidE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to growth factor stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to peptide hormone stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to estrogen stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to hypoxiaE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to gamma radiationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to UV-CE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
fibroblast activationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to actinomycin DE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to formaldehydeE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
amyloid fibril formationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to water-immersion restraint stressE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of apoptotic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of gene expressionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
5S rRNA bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
zinc ion bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
SUMO transferase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
enzyme bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein domain specific bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin protein ligase bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
receptor serine/threonine kinase bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
identical protein bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
peroxisome proliferator activated receptor bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ribonucleoprotein complex bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin protein ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
NEDD8 ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
disordered domain specific bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nuclear bodyE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleolusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytosolE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
plasma membraneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
transcription repressor complexE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
endocytic vesicle membraneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein-containing complexE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID738714Antiproliferative activity against human RKO cells expressing wild type p53 after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738697Cell cycle arrest at human A549 cells expressing wild type p53 assessed as accumulation at S phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 30.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738726Antiproliferative activity against human PC3 cells harboring p53 mutant at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID1118050Inhibition of p53 interaction to MDM2 (unknown origin) by surface plasmon resonance assay2011MedChemComm, , Volume: 2The p53-MDM2/MDMX axis - A chemotype perspective.
AID243263Potency against MDM2 (murine double minute-2 gene) binding to p53; Range =100-300 nM2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
p53 Activation by small molecules: application in oncology.
AID738719Cytotoxicity against human PC3 cells harboring p53 mutant assessed as cell viability at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738698Cell cycle arrest at human A549 cells expressing wild type p53 assessed as accumulation at G2/M phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11.3%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738705Cell cycle arrest at human SJSA1 cells expressing wild type p53 assessed as accumulation at G0/G1 phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 53.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738703Cell cycle arrest at human SJSA1 cells expressing wild type p53 assessed as accumulation at S phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 33.2%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID754224Binding affinity to MDM2 (unknown origin) expressed in Escherichia coli BL21(DE3) after 30 mins by fluorescence polarization assay in presence of P4 peptide2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.
AID1195730Binding affinity to MDM2 (unknown origin)2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
AID738712Cytotoxicity against human A549 cells expressing wild type p53 assessed as cell viability after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738707Cell cycle arrest at human MDA-MB-435S cells harboring p53 mutant assessed as accumulation at G2/M phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 8.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738700Cell cycle arrest at human SJSA1 cells expressing wild type p53 assessed as accumulation at S phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 33.2%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID691697Inhibition of MDM2 binding to p532012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
AID738715Antiproliferative activity against human HepG2 cells expressing wild type p53 after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738699Cell cycle arrest at human A549 cells expressing wild type p53 assessed as accumulation at G0/G1 phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 57.9%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738720Cytotoxicity against human MDA-MB-435S cells harboring p53 mutant assessed as cell viability at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738979Antiproliferative activity against human HeLa cells harboring p53 mutant at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738722Cell cycle arrest at human MDA-MB-435S cells harboring p53 mutant assessed as accumulation at G0/G1 phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 56.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738721Cytotoxicity against human HeLa cells harboring p53 mutant assessed as cell viability at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738702Cell cycle arrest at human SJSA1 cells expressing wild type p53 assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 53.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738709Cytotoxicity against human RKO cells expressing wild type p53 assessed as cell viability after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738723Cell cycle arrest at human MDA-MB-435S cells harboring p53 mutant assessed as accumulation at G2/M phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 8.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738718Cytotoxicity against human SW480 cells harboring p53 mutant assessed as cell viability at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738710Cytotoxicity against human HepG2 cells expressing wild type p53 assessed as cell viability after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738711Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as cell viability after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738704Cell cycle arrest at human SJSA1 cells expressing wild type p53 assessed as accumulation at G2/M phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 13%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738701Cell cycle arrest at human SJSA1 cells expressing wild type p53 assessed as accumulation at G2/M phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 13%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738980Cell cycle arrest at human MDA-MB-435S cells harboring p53 mutant assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 56.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738696Cell cycle arrest at human A549 cells expressing wild type p53 assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 57.9%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738724Cell cycle arrest at human MDA-MB-435S cells harboring p53 mutant assessed as accumulation at S phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 34.4%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738713Antiproliferative activity against human SJSA1 cells expressing wild type p53 after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738725Antiproliferative activity against human SW480 cells harboring p53 mutant at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738708Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as cell viability after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738694Cell cycle arrest at human A549 cells expressing wild type p53 assessed as accumulation at S phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 30.8%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738706Cell cycle arrest at human MDA-MB-435S cells harboring p53 mutant assessed as accumulation at S phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 34.4%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738695Cell cycle arrest at human A549 cells expressing wild type p53 assessed as accumulation at G2/M phase at 10 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11.3%)2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738717Antiproliferative activity against human A549 cells expressing wild type p53 after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738727Antiproliferative activity against human MDA-MB-435S cells harboring p53 mutant at 10 uM after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
AID738716Antiproliferative activity against human HCT116 cells expressing wild type p53 after 5 days by MTS assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.45 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nutlin 3
[no description available]		2.0710stilbenoid
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		4.5940stilbenoid
MI-63
MI-63 : An azaspiro compound resulting from the formal fusion of position 3 of 6-chloro-oxindole with position 3 of (2R,3SS5S)-3-(3-chloro-2-fluorophenyl)-5-(2,2-dimethylpropyl)-N-[2-(morpholin-4-yl)ethyl]pyrrolidine-2-carboxamide. It is a potent inhibitor of the MDM2-p53 interaction.		2.0610azaspiro compound;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
oxindoles;
pyrrolidines;
secondary carboxamide		apoptosis inducer
nutlin-3b
[no description available]		2.0710Nutlin;
piperazinone		anticoronaviral agent
pb 12
[no description available]		3.8730
sar405838
SAR405838: an inhibitor of the interaction of MDM2 and p53; has antineoplastic activity; structure in first source		3.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		04.1430
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.1430